SCHEMBL6958727

SCHEMBL6958727

CC(C)c1ccccc1Sc1c(O)cc(-c2cccc(C(F)(F)F)c2)oc1=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 1/20 0.42
PTPN5 P54829 4/20 0.40
CYP1A1 P04798 1/20 0.40
CYP1B1 Q16678 1/20 0.40
P2RY1 P47900 1/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 1/20 0.37
MEN1 O00255 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.36
CNR2 P34972 1/20 0.36
TP53 P04637 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
SLC9A1 P19634 1/20 0.36
AR P10275 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6964481 0.86 TNKS (0.44) CYP1A2CYP2C19CYP1A1CYP1B1KDM4E
SCHEMBL6961039 0.85 SMN1; SMN2 (0.46) CYP1A2CYP2C19CYP1A1CYP1B1KDM4E
SCHEMBL6961237 0.85 QPCT (0.42) KDM4EHTTALDH1A1MAPTCNR2
SCHEMBL6963792 0.84 GABRP (0.43) CYP1A2CYP1A1CYP1B1KDM4EGAA
SCHEMBL6960601 0.81 AR (0.41) CYP1A2CYP1A1CYP1B1AR
SCHEMBL6963494 0.81 PTGES (0.43) CYP1A2CYP2C19CYP1A1CYP1B1KDM4E
SCHEMBL6959292 0.80 POLB (0.35) CYP1A2CYP2C19KDM4EHTTALDH1A1
SCHEMBL6960294 0.80 QPCT (0.39) CYP1A2CYP1A1CYP1B1HTTALDH1A1
SCHEMBL6964073 0.80 AR (0.41) KDM4EHTTALDH1A1MAPTAR
SCHEMBL6965601 0.80 NPSR1 (0.42) CYP1A2CYP2C19KDM4EGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US claimed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP claimed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO claimed
EP-0729465-B1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE DAVIS & CO (US) 2003-01-22 EP disclosed
US-6005103-A TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS WARNER-LAMBERT COMPANY (US) 1999-12-21 US disclosed
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US disclosed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
EP-0729465-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
WO-1995014013-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed